published meta-analysis   sensitivity analysis   studies

Immunostimulants drugs in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias radiologic improvement (14-day)detailed resultsCai -FAVIPIRAVIR, 2020 6.48 [1.72; 24.44] 6.48[1.72; 24.44]Cai -FAVIPIRAVIR, 202010%80NAnot evaluable adverse eventsdetailed resultsCai -FAVIPIRAVIR, 2020 0.10 [0.03; 0.34] 0.10[0.03; 0.34]Cai -FAVIPIRAVIR, 202010%80NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-07-04 03:54 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567 - roots T: 290